Stocks of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) traded higher last session on Wall Street, down -0.21% to $14.57.
According to the data, Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) has 11 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $9.00, we find $21.50. Given the previous closing price of $14.60, this indicates a potential upside of 47.26 percent. DCPH stock price is now -14.47% away from the 50-day moving average and -7.02% away from the 200-day moving average. The market capitalization of the company currently stands at $1.06B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 4 analysts have issued a hold rating and 6 have given it a buy rating. Brokers who have rated the stock have averaged $21.60 as their price target over the next twelve months.
With the price target maintained at $22, Guggenheim recently Upgraded its rating from Neutral to Buy for Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH). On August 29, 2022, Cowen recently initiated its ‘Outperform’ rating on the stock quoting a target price of $25, while ‘JMP Securities’ rates the stock as ‘Mkt Outperform’.
In other news, Flynn Daniel Lee, Chief Scientific Officer sold 1,370 shares of the company’s stock on Feb 16. The stock was sold for $20,686 at an average price of $15.10. Upon completion of the transaction, the Chief Scientific Officer now directly owns 58,813 shares in the company, valued at $0.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 16, Chief Financial Officer Kelly Thomas Patrick sold 1,370 shares of the business’s stock. A total of $20,686 was realized by selling the stock at an average price of $15.10. This leaves the insider owning 58,795 shares of the company worth $0.86 million. Insiders disposed of 30,094 shares of company stock worth roughly $0.44 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DCPH stock. A new stake in Deciphera Pharmaceuticals Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $47,666,000. WOLVERINE TRADING, LLC invested $25,527,000 in shares of DCPH during the first quarter. In the first quarter, JEFFERIES FINANCIAL GROUP INC. acquired a new stake in Deciphera Pharmaceuticals Inc. valued at approximately $2,766,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in DCPH for approximately $1,321,000. DANA INVESTMENT ADVISORS, INC. purchased a new stake in DCPH valued at around $516,000 in the second quarter. In total, there are 227 active investors with 74.80% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $14.59 for Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH). During the past 12 months, Deciphera Pharmaceuticals Inc. has had a low of $7.11 and a high of $22.76. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.50, and a quick ratio of 4.30. The fifty day moving average price for DCPH is $17.04 and a two-hundred day moving average price translates $15.67 for the stock.
The latest earnings results from Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) was released for Dec, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.6, missing analysts’ expectations of -$0.56 by -0.04. This compares to -$1.51 EPS in the same period last year. The company reported revenue of $36.34 million for the quarter, compared to $24.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 50.19 percent. For the current quarter, analysts expect DCPH to generate $36.01M in revenue.
Deciphera Pharmaceuticals Inc.(DCPH) Company Profile
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
